scholarly journals Cardiovascular Health and Risk Management in Cancer Survivors

2020 ◽  
Vol 18 (7.5) ◽  
pp. 1004-1006
Author(s):  
Javid J. Moslehi
Keyword(s):  
Cardiovascular Disease ◽  
Cancer Survivors ◽  
Cardiovascular System ◽  
Cardiovascular Health ◽  
Checkpoint Inhibitors ◽  
Angiogenesis Inhibitors ◽  
Cardiovascular Complications ◽  
Cancer Treatments ◽  
Cardiovascular Damage ◽  
Similar Risk

Cardio-oncology is a growing field, due to several factors. These include the recognition that similar risk factors predispose people to both cardiovascular disease and cancer. In addition, certain cancers affect the heart, and cancer treatments can have short-term and long-lasting deleterious effects on the cardiovascular system. More than 40 years ago, it became evident that anthracyclines and radiation cause heart damage, and since then the list of cancer treatments that can harm the cardiovascular system has grown to include more modern treatments, such as anti-HER2 agents and angiogenesis inhibitors. Most recently, immune checkpoint inhibitors (ICIs) have been added to the list of cancer treatments that cause cardiovascular damage. ICI-associated myocarditis is a relatively rare but fatal complication that develops rapidly after initiating immunotherapy. Oncologists should be aware of the potential cardiovascular complications of cancer treatments, and should assess the cardiovascular health of all patients about to undergo therapy. Cancer survivors should be assessed and advised about prevention and treatment that may be needed to address cardiovascular disease.

scholarly journals One-year Risks and Burdens of Incident Cardiovascular Disease in COVID-19: Cardiovascular Manifestations of Long COVID

2021 ◽  
Author(s):  
Ziyad Al-Aly ◽  
Benjamin Bowe ◽  
Yan Xie ◽  
Evan Xu
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Health ◽  
Acute Infection ◽  
Cerebrovascular Disorders ◽  
Cardiovascular Complications ◽  
Department Of Veterans Affairs ◽  
Increased Risk ◽  
Health And Disease ◽  
One Year ◽  
Incident Cardiovascular Disease

Abstract The cardiovascular complications of acute COVID-19 are well described; however, a comprehensive characterization of the post-acute cardiovascular manifestations of COVID-19 at one year has not been undertaken. Here we use the US Department of Veterans Affairs national healthcare databases to build a cohort of 151,195 people with COVID-19, 3,670,087 contemporary and 3,656,337 historical controls to estimate risks and 1-year burdens of a set of pre-specified incident cardiovascular outcomes. We show that beyond the first 30 days of infection, people with COVID-19 are at increased risk of incident cardiovascular disease spanning several categories including cerebrovascular disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis, myocarditis, heart failure, and thromboembolic disease. The risks and burdens were evident among those who were non-hospitalized during the acute phase of the infection and increased in a graded fashion according to care setting of the acute infection (non-hospitalized, hospitalized, and admitted to intensive care). Taken together, our results provide evidence that risk and 1-year burden of cardiovascular disease in survivors of acute COVID-19 are substantial. Care pathways of people who survived the acute episode of COVID-19 should include attention to cardiovascular health and disease.

scholarly journals Cardiovascular system and COVID-19

2021 ◽  
Vol 27 (3) ◽  
pp. 16-23
Author(s):  
Damyan Boychev ◽  
Naidenka Zlatareva ◽  
Ivo Petrov
Keyword(s):  
Myocardial Infarction ◽  
Cardiovascular Disease ◽  
Cardiovascular System ◽  
Stable Angina ◽  
Cardiovascular Complications ◽  
Morbidity And Mortality ◽  
Registered Case

The coronavirus disease 2019 (COVID-19) pandemic has affected health and economies around the globe at an unprecedented scale. Since the fi rst registered case of Covid-19 in December of 2019 until May 2021, more than 167 mil people have been infected and more than 3.5 mil have died. Patients with cardiovascular disease are one of the most affected groups. First, because cardiovascular disease, for example, stable angina or past myocardial infarction, weakens system’s abilities of dealing with stress due to infl ammation. Secondly, because COVID-19 is associated with multiple different mechanisms of cardiovascular injury. Developing COVID-19 related cardiovascular complications is associated with increased morbidity and mortality. The goal of this review is to present the known up to this moment mechanisms of cardiovascular injury and complications after COVID-19.

Prevention of Cardiovascular Disease Among Cancer Survivors: the Role of Pre-existing Risk Factors and Cancer Treatments

2017 ◽  
Vol 4 (3) ◽  
pp. 239-247 ◽  
Author(s):  
Derek Rothe ◽  
Ian Paterson ◽  
Nanette Cox-Kennett ◽  
Gabor Gyenes ◽  
Edith Pituskin
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Cancer Survivors ◽  
Cancer Treatments ◽  
Prevention Of Cardiovascular Disease

scholarly journals Exercise Training and Cardiac Rehabilitation in COVID-19 Patients with Cardiovascular Complications: State of Art

Life ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 259
Author(s):  
Mariaconsiglia Calabrese ◽  
Marina Garofano ◽  
Roberta Palumbo ◽  
Paola Di Pietro ◽  
Carmine Izzo ◽  
...  
Keyword(s):  
Exercise Training ◽  
Cardiac Rehabilitation ◽  
Cardiovascular System ◽  
Patient Monitoring ◽  
Scientific Evidence ◽  
Cardiovascular Complications ◽  
Angiotensin Converting Enzyme 2 ◽  
Coronary Syndrome ◽  
Cardiovascular Damage ◽  
Include Heart Failure

Recent scientific literature has investigated the cardiovascular implications of COVID-19. The mechanisms of cardiovascular damage seem to involve the protein angiotensin-converting enzyme 2 (ACE2), to which severe acute respiratory syndrome (SARS) coronavirus-2 (CoV-2) binds to penetrate cells and other mechanisms, most of which are still under study. Cardiovascular sequelae of COVID-19 include heart failure, cardiomyopathy, acute coronary syndrome, arrhythmias, and venous thromboembolism. This article aims to collect scientific evidence by exploiting PubMed, Scopus, and Pedro databases to highlight the cardiovascular complications of COVID-19 and to define the physiotherapy treatment recommended for these patients. Exercise training (ET), an important part of cardiac rehabilitation, is a powerful tool in physiotherapy, capable of inducing significant changes in the cardiovascular system and functional in the recovery of endothelial dysfunction and for the containment of thromboembolic complications. In conclusion, due to the wide variety of possible exercise programs that can be obtained by combining intensity, duration, and speed in various ways, and by adjusting the program based on continuous patient monitoring, exercise training is well suited to the treatment of post-COVID patients with an impaired cardiovascular system of various degrees.

scholarly journals CARDIOVASCULAR DISEASE IN COVID-19 PATIENTS. PART 1.

2020 ◽  
Vol 18 (6) ◽  
pp. 643-647
Author(s):  
V. S. Holyshko ◽  
◽  
V. A. Snezhitskiy ◽  
N. V. Matsiyeuskaya ◽  
◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular System ◽  
Critically Ill Patients ◽  
Medical Problem ◽  
Adverse Outcomes ◽  
The Other ◽  
Cardiovascular Pathology ◽  
Cardiovascular Damage ◽  
The One ◽  
The Impact

The COVID-19 pandemic caused by SARS-CoV-2 is the greatest medical problem of our time. The presence of concomitant cardiovascular pathology in a patient predisposes to a severe course and the formation of adverse outcomes of COVID-19. It is currently known that SARS-CoV-2 infection leads, on the one hand, to exacerbation and decompensation of the patient's cardiovascular disease, on the other hand, it is the origin of acute cardiovascular pathology. Understanding the impact of COVID-19 on the cardiovascular system is essential for providing comprehensive care to critically ill patients. In this review, we summarize the rapidly changing data on cardiovascular damage associated with COVID-19.

Abstract 14594: Association Between Life's Simple 7 and Cardiovascular Disease in Cancer Patients Compared to Noncancer Controls in the Aric Cohort

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Evelyn J Song ◽  
Sui Zhang ◽  
Ana E Prizment ◽  
Elizabeth J Polter ◽  
Elizabeth Selvin ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Cancer Survivors ◽  
Cancer Diagnosis ◽  
Cardiovascular Health ◽  
Cox Regression ◽  
Smoking History ◽  
Incidence Density ◽  
Cvd Risk ◽  
Life’S Simple 7 ◽  
Life's Simple 7

Introduction: Cancer survivors have greater cardiovascular disease (CVD) risk through unclear mechanisms. Little is known about whether Life’s Simple 7 (LS7) metrics differ between persons with and without cancer and if the link between LS7 and CVD is similar in cancer survivors compared to persons without prior cancer. Hypothesis: Persons who develop cancer have poorer LS7 metrics compared to noncancer controls, and an ideal LS7 score is less protective against CVD events in persons with versus those without prior cancer. Methods: A total of 2950 ARIC participants who developed cancer were matched at the time of cancer diagnosis (incidence density sampling) on age, sex, race, and study center, to 5900 noncancer controls. We compared LS7 metrics in individuals who developed cancer (assessed prior to cancer diagnosis) and in matched controls. We used Cox regression to evaluate the prospective association between LS7 score and CVD events (coronary heart disease, heart failure or stroke) stratified by cancer status, with test for interaction between LS7 and cancer. Results: Compared to matched noncancer controls, those who developed cancer were less likely to have an ideal smoking history, body mass index, glucose control, physical activity levels, and diet (defined by LS7 metrics; Table ). Overall those with cancer were less likely to have an ideal LS7 score than noncancer controls (18 vs 23% p<0.0001). Compared to inadequate, an ideal LS7 score was similarly associated with lower CVD risk in persons with and without cancer (HRs 0.37 [95% CI: 0.26-0.52] and 0.40 [95% CI: 0.32-0.50], respectively), with no interaction between LS7 score and cancer status (p = 0.59). Conclusions: Individuals who develop cancer have poorer overall cardiovascular health as reflected by the LS7 score, but an ideal LS7 score is associated with similar cardio-protection in those with and without cancer. Cancer survivors may benefit from interventions targeting cardiovascular health metrics.

scholarly journals Cardiovascular Disease and Psychiatric Comorbidity: The Potential Role of Perseverative Cognition

2009 ◽  
Vol 2009 ◽  
pp. 1-8 ◽  
Author(s):  
Britta A. Larsen ◽  
Nicholas J. S. Christenfeld
Keyword(s):  
Cardiovascular Disease ◽  
Psychiatric Disorders ◽  
Potential Role ◽  
Cardiovascular Health ◽  
Acute Stress ◽  
Stressful Events ◽  
Disease Etiology ◽  
Perseverative Cognition ◽  
Cardiovascular Damage

The high comorbidity between psychiatric disorders and cardiovascular disease has received increasing attention, yet little is known about the processes linking the two. One plausible contributing mechanism is the tendency of those with psychiatric disorders to ruminate on stressful events. This phenomenon, sometimes called perseverative cognition, can extend the psychological and physiological effects of stress, which could contribute to cardiovascular disease etiology. In this paper, we discuss the potential role of perseverative cognition in mediating the relationship between psychiatric illness and cardiovascular disease. Rumination can delay physiological recovery from acute stress, which in turn has been found to predict future cardiovascular health. This delayed recovery could act as a mechanism in the longitudinal link between worry and cardiovascular health. The cognitive inflexibility that characterizes mood and anxiety disorders may then contribute to disease not by producing greater reactivity, but instead through extending activation, increasing the risks for cardiovascular damage.

scholarly journals COVID-19 and the Cardiovascular System: How the First PostModern Pandemic ‘Weakened’ our Hearts

2020 ◽  
Vol 3 ◽  
pp. e15
Author(s):  
Syeda Tasneem Towhid ◽  
◽  
Nadira Naznin Rakhi ◽  
ASM Shamsul Arefin ◽  
Otun Saha ◽  
...  
Keyword(s):  
Cardiovascular System ◽  
Cardiac Injury ◽  
Age Groups ◽  
Signs And Symptoms ◽  
Holistic Approach ◽  
Cardiovascular Complications ◽  
Cardiac Complications ◽  
Cardiovascular Damage ◽  
Preventative Measures ◽  
Life Threatening

The global spread of SARS-CoV-2 with its diverse signs and symptoms manifested in COVID-19 patients across different age groups and geographic locations perplexed the clinicians and public health experts. Emerging variants of SARS-CoV-2 through continuous mutation with a limited arsenal of treatment made the study of viral pathogenesis and factors associated with disease outcomes in a holistic approach inevitable, among which pre-existing cardiovascular complications were found to be significantly associated with adverse outcome of COVID-19. In addition, COVID-19 has already been reported to cause cardiac injury and different cardiovascular complications in patients irrespective of preexisting cardiovascular complications, which highlights the importance of recognizing the complications at the onset, although these arising complications might be an indirect effect of SARS-CoV-2 induced cytokine storm or hypoxia rather the virus itself. Also, the drugs used for the clinical management of the patients may have an impact on the induced cardiac complications. Thus, the effect of SARS-CoV-2 on the cardiovascular system needs to be investigated in order to predict the clinical outcome and to devise a proper treatment strategy. Besides, the interaction of vaccines or therapeutics to be approved with the cardiovascular system needs to be evaluated to avoid confounding effects leading to cardiovascular complications followed by post-approval retraction. However, potential biomarkers (eg. troponin, D-dimers, fibrin) associated with cardiac injury may be potentially useful in predicting life-threatening conditions early enough to save lives. In conclusion, this review summarizes the molecular pathogenesis of cardiovascular damage caused by SARS-CoV-2 in COVID-19 patients, as well as prescribed treatment and preventative measures.

scholarly journals C1q Complement/Tumor Necrosis Factor-Associated Proteins in Cardiovascular Disease and COVID-19

Proteomes ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 12
Author(s):  
Yaoli Xie ◽  
Zhijun Meng ◽  
Jia Gao ◽  
Caihong Liu ◽  
Jing Wang ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Tumor Necrosis Factor ◽  
Cardiovascular System ◽  
Tumor Necrosis ◽  
Current Knowledge ◽  
Immune Surveillance ◽  
Treatment Strategies ◽  
Cardiovascular Complications ◽  
Associated Proteins ◽  
Necrosis Factor

With continually improving treatment strategies and patient care, the overall mortality of cardiovascular disease (CVD) has been significantly reduced. However, this success is a double-edged sword, as many patients who survive cardiovascular complications will progress towards a chronic disorder over time. A family of adiponectin paralogs designated as C1q complement/tumor necrosis factor (TNF)-associated proteins (CTRPs) has been found to play a role in the development of CVD. CTRPs, which are comprised of 15 members, CTRP1 to CTRP15, are secreted from different organs/tissues and exhibit diverse functions, have attracted increasing attention because of their roles in maintaining inner homeostasis by regulating metabolism, inflammation, and immune surveillance. In particular, studies indicate that CTRPs participate in the progression of CVD, influencing its prognosis. This review aims to improve understanding of the role of CTRPs in the cardiovascular system by analyzing current knowledge. In particular, we examine the association of CTRPs with endothelial cell dysfunction, inflammation, and diabetes, which are the basis for development of CVD. Additionally, the recently emerged novel coronavirus (COVID-19), officially known as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been found to trigger severe cardiovascular injury in some patients, and evidence indicates that the mortality of COVID-19 is much higher in patients with CVD than without CVD. Understanding the relationship of CTRPs and the SARS-CoV-2-related damage to the cardiovascular system, as well as the potential mechanisms, will achieve a profound insight into a therapeutic strategy to effectively control CVD and reduce the mortality rate.

scholarly journals Cardiovascular System and SARS-CoV-2: Etiology, Physiopathology and Clinical Presentation: A Systematic Review

2021 ◽  
Author(s):  
Jucier Gonçalves Júnior ◽  
Estelita Lima Cândido ◽  
Gislene Farias de Oliveira ◽  
Modesto Leite Rolim Neto
Keyword(s):  
Systematic Review ◽  
Cardiovascular Disease ◽  
Cardiovascular System ◽  
Clinical Presentation ◽  
Meta Analysis ◽  
Cardiovascular Complications ◽  
Review Of The Literature ◽  
Governmental Organizations ◽  
System A ◽  
The Impact

During SARS-CoV-1 and Middle East Respiratory Distress Syndrome (MERS) outbreaks it was observed a particularly elevated incidence of cardiovascular disease among patients. With COVID-19, this correlation becomes evident again. However, the cardiovascular impacts by COVID-19 pandemic are not yet well established although publications about its potential deleterious effects are constant. Thus, aimed to carry a systematic review of the literature with meta-analysis, the following question was used as a guide: what practical contributions does the scientific literature produced in the period of 2019-2020 has to offer about the impact of the COVID-19 on cardiovascular system? A systematic review of the literature using the Virtual Health Library (VHL) and PubMed with the following descriptors: #1 “cardiovascular disease” [MeSH] AND #2 “COVID-19” [keyword], as well as their equivalents in the Portuguese and Spanish language, during the period from December 2019 to March 2020 was performed. One hundred articles were found in Pubmed and twenty-seven were selected. In VHL there are 59 articles and four were selected totaling thirty-one papers. The findings were then divided into three subcategories: Etiology, Physiopathology and Risk factors of SARS-CoV-2 in Cardiovascular System; Clinical presentation, laboratory markers and imagenological aspects of SARS-CoV-2 in cardiovascular system; and Anti-Hypertensive Drugs, Cardiovascular System and SARS-CoV-2. When it comes to the cardiovascular system, these issues are aggravated and urge as a joint commitment from researchers, medical and governmental organizations to carry out more robust studies with bold methodologies aimed at mapping prognostic factors and assertive therapeutic approaches in the management of cardiovascular complications of COVID- 19.

Sign in / Sign up

Export Citation Format

Share Document